Literature DB >> 118839

Binding of serum amyloid P-component (SAP) by amyloid fibrils.

M B Pepys, R F Dyck, F C de Beer, M Skinner, A S Cohen.   

Abstract

Serum amyloid P-component (protein SAP) was found to bind in vitro to isolated amyloid fibrils of both primary and secondary types. The binding was strictly calcium-dependent, optimal uptake requiring at least 0.5 mM calcium ion. Using normal human serum as the source of protein SAP different fibril preparations became saturated with between 5--20 micrograms of SAP per mg dry weight of fibril. Isolated pure protein SAP bound in greater amounts. In control experiments SAP did not bind significantly to collagen fibrils, sheep erythrocytes, plastic shavings, or the following immobilized proteins: human kappa or lambda Bence-Jones proteins; human; rabbit or mouse IgG; human serum albumin. C-reactive protein, which resembles protein SAP structurally but has calcium-dependent specificity for different ligands, bound significantly to only one of five different amyloid fibril preparations.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 118839      PMCID: PMC1537850     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  IMMUNOLOGIC STUDIES ON A PROTEIN EXTRACTED FROM HUMAN SECONDARY AMYLOID.

Authors:  E S CATHCART; F R COMERFORD; A S COHEN
Journal:  N Engl J Med       Date:  1965-07-15       Impact factor: 91.245

2.  Isolation of C-reactive protein by affinity chromatography.

Authors:  M B Pepys; A C Dash; M J Ashley
Journal:  Clin Exp Immunol       Date:  1977-10       Impact factor: 4.330

3.  Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins).

Authors:  A P Osmand; B Friedenson; H Gewurz; R H Painter; T Hofmann; E Shelton
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

4.  The location of three collagen types in skeletal muscle.

Authors:  V C Duance; D J Restall; H Beard; F J Bourne; A J Bailey
Journal:  FEBS Lett       Date:  1977-07-15       Impact factor: 4.124

5.  The ultrastructure of human amyloid as revealed by the negative staining technique.

Authors:  H A Bladen; M U Nylen; G G Glenner
Journal:  J Ultrastruct Res       Date:  1966-03

6.  Plasma protein constituents of amyloid fibrils.

Authors:  E S Cathcart; F A Wollheim; A S Cohen
Journal:  J Immunol       Date:  1967-08       Impact factor: 5.422

7.  Analogues in other mammals and in fish of human plasma proteins, C-reactive protein and amyloid P component.

Authors:  M B Pepys; A C Dash; T C Fletcher; N Richardson; E A Munn; A Feinstein
Journal:  Nature       Date:  1978-05-11       Impact factor: 49.962

8.  Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin.

Authors:  M H Kaplan; J E Volanakis
Journal:  J Immunol       Date:  1974-06       Impact factor: 5.422

9.  Murine amyloid protein AA in casein-induced experimental amyloidosis.

Authors:  M Skinner; T Shirahama; M D Benson; A S Cohen
Journal:  Lab Invest       Date:  1977-04       Impact factor: 5.662

10.  Immunologic studies of the major nonimmunoglobulin protein of amyloid. I. Identification and partial characterization of a related serum component.

Authors:  M Levin; M Pras; E C Franklin
Journal:  J Exp Med       Date:  1973-08-01       Impact factor: 14.307

View more
  74 in total

1.  Accumulation of pro-apolipoprotein A-II in mouse senile amyloid fibrils.

Authors:  K Higuchi; K Kogishi; J Wang; C Xia; T Chiba; T Matsushita; M Hosokawa
Journal:  Biochem J       Date:  1997-08-01       Impact factor: 3.857

2.  A primed state exists in vivo following histological regression of amyloidosis.

Authors:  P N Hawkins; M B Pepys
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

3.  Amyloid in familial amyloidosis, Finnish type, is antigenically and structurally related to gelsolin.

Authors:  M Haltia; J Ghiso; F Prelli; G Gallo; S Kiuru; H Somer; J Palo; B Frangione
Journal:  Am J Pathol       Date:  1990-06       Impact factor: 4.307

4.  Diagnosis and treatment of amyloidosis.

Authors:  P N Hawkins
Journal:  Ann Rheum Dis       Date:  1997-11       Impact factor: 19.103

5.  Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis.

Authors:  G A Tennent; L B Lovat; M B Pepys
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

6.  Hamster female protein, a sex-limited pentraxin, is a constituent of Syrian hamster amyloid.

Authors:  J E Coe; M J Ross
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

7.  Polymerization of intact beta 2-microglobulin in tissue causes amyloidosis in patients on chronic hemodialysis.

Authors:  P D Gorevic; P C Munoz; T T Casey; C R DiRaimondo; W J Stone; F C Prelli; M M Rodrigues; M D Poulik; B Frangione
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

Review 8.  Novel drugs targeting transthyretin amyloidosis.

Authors:  Mazen Hanna
Journal:  Curr Heart Fail Rep       Date:  2014-03

9.  On the association between amyloid fibrils and glycosaminoglycans; possible interactive role of Ca2+ and amyloid P-component.

Authors:  T Stenstad; J H Magnus; K Syse; G Husby
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

10.  Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

Authors:  Karl Bodin; Stephan Ellmerich; Melvyn C Kahan; Glenys A Tennent; Andrzej Loesch; Janet A Gilbertson; Winston L Hutchinson; Palma P Mangione; J Ruth Gallimore; David J Millar; Shane Minogue; Amar P Dhillon; Graham W Taylor; Arthur R Bradwell; Aviva Petrie; Julian D Gillmore; Vittorio Bellotti; Marina Botto; Philip N Hawkins; Mark B Pepys
Journal:  Nature       Date:  2010-10-20       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.